Legend-Backed Immunotherapy Firm Shanghai Cell Therapy Group Co. Secures $136M Series C Round

Login to View

Shanghai Cell Therapy Group Co., a Chinese biotech company, has completed an RMB925 million (US$135.71 million) series C round of financing, led by China Pacific Insurance Company, Haier Capital and China Industrial Asset Management Limited, according to an announcement yesterday.

Continue reading with a China Money Network subscription

Join Now

Already have an account or paid subscription? Log in